Joerg Thomas B.
- Country
- Germany
- Department
- Klinik für Innere Medizin I – Hämato-Onkologie & Rheumatologie
Research Overview
- Efficacy and Safety Evaluation of Venetoclax and Obinutuzumab Retreatment in Patients with Recurrent Chronic Lymphocytic Leukemia
- A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17
- Phase III Non-Inferiority Trial of Lenalidomide, Bortezomib, Dexamethasone, and Isatuximab in Newly Diagnosed Multiple Myeloma Patients
Data & Insights
Has run more than one trial at 215 of 394 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating various blood cancers with particular emphasis on multiple myeloma and lymphoid neoplasms. Their work encompasses innovative therapeutic approaches for both newly diagnosed and relapsed cases.
- Multiple Myeloma Treatment Strategies
- Non-Hodgkin Lymphomas
- Diffuse Large B-cell Lymphoma
- Follicular Lymphoma
Leukemia Management
Focuses on advanced therapeutic approaches for various types of leukemia, including chronic lymphocytic leukemia and acute lymphoblastic leukemia. The investigator works with both treatment-naive and relapsed/refractory cases.
- Philadelphia-Chromosome Positive ALL
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
Novel Therapeutic Approaches
Implements cutting-edge treatment modalities incorporating targeted therapies and combination treatments. The investigator evaluates novel agents including monoclonal antibodies and kinase inhibitors.
- Targeted Molecular Therapies
- Immunotherapy Applications
- Novel Drug Combinations
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.